Merck Kgaa Dm 5 (MKGAF) 107.3000 $MKGAF Forget
Post# of 273242
Posted On: 09/19/2016 7:11:55 PM
Merck Kgaa Dm 5 (MKGAF) 107.3000 $MKGAF
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 32.48 (-0.10), ENDP: 20.06 (-0.79), VRX: 27.10 (-0.18), BSTC: 41.82 (-0.94), MYL: 41.49 (-0.30), TEVA: 50.70 (-1.04), USNA: 135.49 (-0.71)
Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 63.75 (-0.55), MYL: 41.49 (-0.30), SNY: 38.70 (+0.27)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.66 (+0.16), ANIP: 63.75 (-0.55), XON: 27.92 (+0.07)
Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 3:29AM CDT
Merck KGaA (MKGAF) second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents.
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 26.18 (+0.03), IRWD: 14.89 (-0.03), PFE: 33.65 (-0.29)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29), BMY: 55.08 (-0.52)
Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 16.77 (+0.03), BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29)
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 0.82 (unch), ANIP: 63.75 (-0.55), XON: 27.92 (+0.07)
Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 33.65 (-0.29), HZNP: 19.12 (-0.16), ARNA: 1.69 (+0.03)
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 7.81 (-0.26), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 7.81 (-0.26), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)
Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)
Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 245.29 (+0.10), PFE: 33.65 (-0.29), LLY: 79.16 (+0.36)
Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 27.92 (+0.07), BXLT: 46.02 (-0.18), ANIK: 47.49 (+0.12)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)
Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 20.06 (-0.79), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 98.11 (+1.25), NVET: 4.20 (-0.01), REGN: 402.83 (-5.80)
Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 33.65 (-0.29), LLY: 79.16 (+0.36), NVS: 79.94 (+0.60)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 32.48 (-0.10), ENDP: 20.06 (-0.79), VRX: 27.10 (-0.18), BSTC: 41.82 (-0.94), MYL: 41.49 (-0.30), TEVA: 50.70 (-1.04), USNA: 135.49 (-0.71)
Mylan (MYL) Draws Flak for Over Pricing EpiPen, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 6:41AM CDT
Mylan's (MYL) shares took a beating after U.S. senators raised questions about the company's massive price hike of epinephrine auto-injector, EpiPen.
ANIP: 63.75 (-0.55), MYL: 41.49 (-0.30), SNY: 38.70 (+0.27)
Intrexon (XON) Reports Wider Loss in Q2, Revenues Increase
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 4:10PM CDT
Intrexon (XON) reported a loss of 42 cents per share in second-quarter 2016, compared to the year-ago figure of 37 cents.
ZIOP: 5.66 (+0.16), ANIP: 63.75 (-0.55), XON: 27.92 (+0.07)
Merck KGaA (MKGAF) Q2 Earnings Fall, Guides Up on Sales
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:39AM CDT
Merck KGaA (MKGAF) reported second-quarter 2016 earnings of 80 cents on sales of $4.3 billion.
BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)
Merck KGaA (MKGAF) Q2 Earnings Fall But View Raised
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 3:29AM CDT
Merck KGaA (MKGAF) second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents.
What's in Store for Merck KGaA (MKGAF) in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:06AM CDT
Merck KGaA (MKGAF) is scheduled to report second-quarter 2016 earnings results on Aug 4.
IPXL: 26.18 (+0.03), IRWD: 14.89 (-0.03), PFE: 33.65 (-0.29)
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29), BMY: 55.08 (-0.52)
Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 16.77 (+0.03), BMRN: 98.11 (+1.25), PFE: 33.65 (-0.29)
Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 0.82 (unch), ANIP: 63.75 (-0.55), XON: 27.92 (+0.07)
Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 33.65 (-0.29), HZNP: 19.12 (-0.16), ARNA: 1.69 (+0.03)
Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 7.81 (-0.26), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)
Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 7.81 (-0.26), PFE: 33.65 (-0.29), ANIK: 47.49 (+0.12)
Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)
Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 245.29 (+0.10), PFE: 33.65 (-0.29), LLY: 79.16 (+0.36)
Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 27.92 (+0.07), BXLT: 46.02 (-0.18), ANIK: 47.49 (+0.12)
Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 61.33 (-0.95), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)
Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 20.06 (-0.79), PFE: 33.65 (-0.29), CORT: 5.99 (+0.23)
BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 98.11 (+1.25), NVET: 4.20 (-0.01), REGN: 402.83 (-5.80)
Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 33.65 (-0.29), LLY: 79.16 (+0.36), NVS: 79.94 (+0.60)
(0)
(0)Scroll down for more posts ▼